The company saw a drop in its Q4 sample accessions compared to the same quarter last year, but posted increases in both testing and revenues for the full year.
Angle aims to show that clinicians can determine HER-2 status by subjecting harvested circulating tumor cells to fluorescence in situ hybridization (FISH).
Liquid biopsy companies are increasingly recognizing the value of analyzing not just circulating tumor DNA, but biomarkers like CTCs, methylation, and proteins.
The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.
The company plans to continue to validate the liquid biopsy system for use in cancer diagnostics, therapy management, and patient monitoring.
This is Biocept's third BCBS contract and enables cancer patients to access the company's testing services in network under their Wellmark health plans.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
The companies will comarket Clearbridge's ClearCell CTC system and Leica's Bond Rx staining platform.
The company believes its system, launched earlier this year, can outperform other microfluidic technologies, yielding samples with fewer white blood cells that allow better genomic analyses.
About £3.7 million ($4.9 million) of proceeds from the placement would go toward the acquisition, while remaining funds will support assay development validation, and working capital.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.